openPR Logo
Press release

FDA Releases Draft Guidance on CMC For Individualized ASO Therapies

07-08-2022 12:06 PM CET | Health & Medicine

Press release from: SAE Media Group

P-382 PR2

P-382 PR2

SAE Media Group proudly presents the return of the Oligonucleotide Therapeutics & Delivery Conference on the 21st and 22nd September 2022 in London, UK. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

Personalized medicine continues to be at the cutting edge of healthcare, pharmaceuticals, and biotechnology. For patients afflicted with a unique disease state or those with diseases resistant or inadequately treated by existing therapies, personalized treatments are a last, best hope.

However, for pharmaceutical companies, the safe and ethical development of individualized treatments is, as with any new pharmaceutical, an expensive and time-intensive endeavor. This creates a conflict between the need for these therapies and the lack of a large patient population that may participate in clinical trials and ultimately purchase an approved treatment to offset the initial development costs.

This issue was recognised by the FDA and on December 7th, 2021, a new draft guidance was published: "IND Submissions For Individualized Antisense Oligonucleotide Drug Products For Severely Debilitating Or Life-Threatening Diseases: Chemistry, Manufacturing, And Controls Recommendations, Guidance For Sponsor-Investigators.1"*

The CMC Guidance entails:
•difficulties inherent in manufacturing these individualized treatments
•in turn it offers research and manufacturers the opportunity to create policies and procedures that are more likely to be condoned by the FDA in an IND submission

Presenting on this in more detail at the conference will be Chris Chorley, Associate Director, Global Regulatory CMC from Biogen who will speak about "Current CMC Regulatory Challenges In ASO Development" and Sergio Leone, Research Associate, MRC Toxicology Unit from University of Cambridge who will be presenting on "Molecular Mechanisms Of Antisense Oligonucleotide Cytotoxicity".

Chris Chorley's presentation will be touching on:

•Overview of key CMC regulatory challenges during the clinical development phase
•Regulatory strategies for use of platform data and prior knowledge

Sergio Leone's presentation will be touching on:

•Introduction to the mechanistic action of ASOs in cells after delivery
•Insight into in vivo and in vitro models for the study of ASO cytotoxicity
•Exploring molecular mechanisms of ASO cytotoxicity to better design future ASO therapeutics
•Discussion of balancing safety and efficacy of ASOs

There will also be two pre-conference workshops on 20th September 2022 in London UK.

The first workshop will be discussing "Oligonucleotide Therapies- Overcoming The Challenges Of Delivery" led by Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge, Nick Lench, Executive Director, UKRI/MRC Nucleic Acid Therapy (NATA) and Peter Oliver, Head of Biology, UKRI/MRC Nucleic Acid Therapy (NATA).

The second workshop will be focused on "Managing CMC Activities For The Development Of Oligonucleotide Therapeutics" and this will be led by Mia Kiistala, Principal Consultant, Aurora CMC Consulting.

Interested parties can register for the conference and workshop at: http://www.oligonucleotide.co.uk

For sponsorship opportunities, please contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk

For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email ngaloria@smi-online.co.uk

2nd Annual Oligonucleotide Therapeutics & Delivery Conference
21-22 September 2022
London, UK
Sponsors & Exhibitors: Catalent | ChemGenes | NOF Corporation | Wuxi App Tech
http://www.oligonucleotide.co.uk

Source*: http://www.cellandgene.com

India House, 45 Curlew Street

---------- END ----------

About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Releases Draft Guidance on CMC For Individualized ASO Therapies here

News-ID: 2674958 • Views:

More Releases from SAE Media Group

Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
SAE Media Group reports: Conference co-chairs invite delegates to join the anticipated 6th Annual 3D Cell Culture Conference SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. The 2023 Conference theme is on exploring the implementation of complex in-vitro models for drug development Visit the website at http://www.3d-cellculture.com/PR2 to find out
Exploring the Implementation of Complex In-vitro Models for Drug Development
Exploring the Implementation of Complex In-vitro Models for Drug Development
SAE Media Group reports: Agenda and speaker overview released for the 6th Annual 3D Cell Culture Conference, London, UK SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. 3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to
Co-Chairs from Aerie Pharmaceuticals & Santen Inc USA Invite Industry Experts to join Ophthalmic Drugs
Co-Chairs from Aerie Pharmaceuticals & Santen Inc USA Invite Industry Experts to …
The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies. Further key areas will be
We listened your feedback for Transdermal and Microneedle Drug Delivery Conference
We listened your feedback for Transdermal and Microneedle Drug Delivery Conferen …
SAE Media Group's Transdermal and Microneedle Drug Delivery conference returns to London for the 2nd year on 23 - 24 January 2023 and will focus on exploring the advances in microneedle diagnostics through case studies and real-world examples, whilst engaging in modern strategies for topical and transdermal drug delivery. Vaccine delivery will be a significant aspect of this year's agenda with a focus on microneedle delivery technologies as a mode for

All 5 Releases


More Releases for Oligonucleotide

Oligonucleotide Synthesis Market Size and Share 2022-2027
According to IMARC Group's latest report, titled "Oligonucleotide Synthesis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", the global oligonucleotide synthesis market reached a value of US$ 2.4 Billion in 2021. Oligonucleotide synthesis is the chemical synthesis of little fragments of nucleic acids that are produced through enzymatic chemistry and genetic engineering. It is used in laboratories for diagnostics, academic, industrial, and therapeutic applications. Oligonucleotide synthesis helps in building
Oligonucleotide Synthesis Market Growing with Rising Cancer Burden
The most-prominent factors leading to the growth of the oligonucleotide synthesis market are the technological advancements in the field, increasing government support, rising number of research studies related to synthetic biology, and surging incidence of infections and cancer. As a result, the worth of the sales of synthesized oligonucleotides will increase from $1.5 billion in 2017 to $2.8 billion by 2023, at a 10.8% CAGR during the forecast period (2018–2023).
Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthes …
Researchmoz added latest report "Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment to Hold 70% Market Share by 2025". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Our new research report on the global oligonucleotide synthesis market gives a brief overview of the global market. The report includes projections on the global oligonucleotide synthesis
Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment …
Research Report on "Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment to Hold 70% Market Share by 2025". Our new research report on the global oligonucleotide synthesis market gives a brief overview of the global market. The report includes projections on the global oligonucleotide synthesis market revenue growth and the factors likely to impact this growth during the period of forecast. The report describes the scenario of
Global Oligonucleotide Market Research Report Forecast 2017-2021
The report, titled Global Oligonucleotide Market 2017 is a methodical research study based on the Oligonucleotide market, analyzing the competitive framework of the industry in the world. Using efficient analytical tools such as SWOT analysis and Porter’s five forces analysis, the report provides a comprehensive assessment of the Oligonucleotide market. The report estimates the market size in terms of volume (kilo tons) and revenue (US$) produced, whereas, the key segments and
Oligonucleotide Synthesis Market 2017 Development Trends
This report studies the global Oligonucleotide Synthesis market, analyzes and researches the Oligonucleotide Synthesis development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Agilent Technologies Biosearch Technologies Eurofins Genomics Eurogentec Integrated DNA Technologies Merck KGAA Thermo Fisher Scientific GeneDesign Bio-Synthesis - CRO/CMO Life Sciences Company Bioautomation GE Healthcare LGC Biosearch Technologies NITTO Denko Avecia For more information about this report at http://www.reportsweb.com/global-oligonucleotide-synthesis-market-size-status-and-forecast-2022 Market segment by Regions/Countries, this report